These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1181 related items for PubMed ID: 25713985

  • 41. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect.
    Germain V, Scherlinger M, Barnetche T, Schaeverbeke T, Fédération Hospitalo-universitaire ACRONIM.
    Ann Rheum Dis; 2020 Jan; 79(1):e11. PubMed ID: 30352888
    [No Abstract] [Full Text] [Related]

  • 42. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
    Glintborg B, Sørensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, Hansen IMJ, Jensen DV, Manilo N, Espesen J, Klarlund M, Grydehøj J, Dieperink SS, Kristensen S, Olsen JS, Nordin H, Chrysidis S, Dalsgaard Pedersen D, Sørensen MV, Andersen LS, Grøn KL, Krogh NS, Pedersen L, Hetland ML, all departments of rheumatology in Denmark.
    Ann Rheum Dis; 2017 Aug; 76(8):1426-1431. PubMed ID: 28473425
    [Abstract] [Full Text] [Related]

  • 43. CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease.
    Schulze K, Koppka N, Lutter F, Brandhorst G, Schreiber S, Helwig U.
    Biologicals; 2016 Sep; 44(5):463-6. PubMed ID: 27435444
    [Abstract] [Full Text] [Related]

  • 44. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
    Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, den Broeder AA.
    Arthritis Rheumatol; 2018 Jan; 70(1):60-68. PubMed ID: 29045077
    [Abstract] [Full Text] [Related]

  • 45. The use of biosimilars in paediatric inflammatory bowel disease.
    Jongsma MME, Vulto A, de Ridder L.
    Curr Opin Pediatr; 2017 Oct; 29(5):560-565. PubMed ID: 28692448
    [Abstract] [Full Text] [Related]

  • 46. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
    Codreanu C, Šírová K, Jarošová K, Batalov A.
    Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591
    [Abstract] [Full Text] [Related]

  • 47. Inflammatory diseases: Integrating biosimilars into clinical practice.
    Feldman SR.
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
    [Abstract] [Full Text] [Related]

  • 48. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Cohen SB, Alten R, Kameda H, Hala T, Radominski SC, Rehman MI, Palaparthy R, Schumacher K, Schmitt S, Hua SY, Ianos C, Sewell KL.
    Arthritis Res Ther; 2018 Jul 27; 20(1):155. PubMed ID: 30053896
    [Abstract] [Full Text] [Related]

  • 49. Biosimilars for the management of rheumatoid arthritis: economic considerations.
    Gulácsi L, Brodszky V, Baji P, Kim H, Kim SY, Cho YY, Péntek M.
    Expert Rev Clin Immunol; 2015 Jul 27; 11 Suppl 1():S43-52. PubMed ID: 26395836
    [Abstract] [Full Text] [Related]

  • 50. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?
    Lee H.
    AAPS J; 2014 Jan 27; 16(1):22-6. PubMed ID: 24114449
    [Abstract] [Full Text] [Related]

  • 51. Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand.
    Mahakkanukrauh A, Chaiamnuay S, Koolvisoot A, Kitamnuayphong T, Manavathongchai S, Osiri M, Louthrenoo W, Uea-Areewongsa P, Ahn K, Jung N, Kim M, Lee S, Kim H, Kim S.
    Immunotherapy; 2023 Oct 27; 15(14):1143-1155. PubMed ID: 37589164
    [Abstract] [Full Text] [Related]

  • 52. A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.
    Bellinvia S, Ashraf M, Polosa R, Edwards C.
    Immunotherapy; 2017 Nov 27; 9(14):1133-1142. PubMed ID: 29067885
    [Abstract] [Full Text] [Related]

  • 53. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health.
    Braun J, Kudrin A.
    Biologicals; 2016 Jul 27; 44(4):257-266. PubMed ID: 27117857
    [Abstract] [Full Text] [Related]

  • 54. An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases.
    Wook Hong S, Kim YG, Ye BD.
    Immunotherapy; 2020 Jun 27; 12(9):609-623. PubMed ID: 32517574
    [Abstract] [Full Text] [Related]

  • 55. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.
    Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ureña S, Lim M, Lee YA, Lee SJ, Kim H, Yoo DH, Braun J.
    Ann Rheum Dis; 2013 Oct 27; 72(10):1605-12. PubMed ID: 23687259
    [Abstract] [Full Text] [Related]

  • 56. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T, Letkovsky J.
    Eur J Gastroenterol Hepatol; 2014 Jun 27; 26(6):581-7. PubMed ID: 24722561
    [Abstract] [Full Text] [Related]

  • 57. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
    Ye BD, Pesegova M, Alexeeva O, Osipenko M, Lahat A, Dorofeyev A, Fishman S, Levchenko O, Cheon JH, Scribano ML, Mateescu RB, Lee KM, Eun CS, Lee SJ, Lee SY, Kim H, Schreiber S, Fowler H, Cheung R, Kim YH.
    Lancet; 2019 Apr 27; 393(10182):1699-1707. PubMed ID: 30929895
    [Abstract] [Full Text] [Related]

  • 58. Biosimilars: Rationale and current regulatory landscape.
    Olech E.
    Semin Arthritis Rheum; 2016 Apr 27; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [Abstract] [Full Text] [Related]

  • 59. Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry.
    Kim HA, Lee E, Lee SK, Park YB, Shin K.
    BioDrugs; 2020 Aug 27; 34(4):529-539. PubMed ID: 32696266
    [Abstract] [Full Text] [Related]

  • 60. [Biosimilars in rheumatology. Development and results of clinical trials].
    Alten R.
    Z Rheumatol; 2015 Oct 27; 74(8):682-8. PubMed ID: 26347121
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 60.